Part 4: Metastatic prostate cancer and HRR defects

Bookmark and Share
Published: 23 Jul 2021
Views: 2106
Rating:
Save
PARP inhibition in the treatment of prostate cancer

This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.

Prostate cancer is the second most common cancer in men worldwide. Although the incidence of autopsy-detected cancers is roughly the same in different parts of the world, the incidence of clinically diagnosed prostate cancer varies widely.

This video explores the role HRR pathway in metastatic prostate cancer and the treatment options available for this type of prostate cancer.

To learn about when to test for prostate cancer click here.

To learn about who to test for prostate cancer click here.

To learn about how to test for prostate cancer click here.

To learn about BRCA 1-2 mutations and prostate cancer click here.

To watch an expert panel discussion on the role of testing in prostate cancer treatment click here.

To watch a discussion on the latest on PARPi and other treatments for mCRPC click here here.

This programme has been supported by an unrestricted educational grant from AstraZeneca.